Gubra to focus discontinued Bayer collaboration towards overweight and obesity
CEO Henrik Blou does not want to specify when a new collaboration with a focus on obesity could be in place.
It has been an eventful end to the summer for Danish biotech Gubra, which is active in both contract research and the development of its own pharmaceuticals.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Bayer scraps collaboration with Danish biotech company Gubra
For subscribers
